Original articleVascular Endothelial Growth Factor Gene and the Response to Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in High Myopia
Section snippets
Methods
All procedures in this study adhered to the tenets of the Declaration of Helsinki. The institutional review board and ethics committee of each institute involved approved the protocols of this study. All patients were fully informed of the purpose and procedures of this study, and written consent was obtained from each patient.
Results
There were 83 patients with CNV in highly myopic eyes who underwent treatment with bevacizumab (62 eyes), pegaptanib (3 eyes), or ranibizumab (18 eyes). All patients were followed for at least 12 months. Anti-VEGF therapy was initiated by a single injection in 65 eyes (initial loading dose [−] group) and by 3 monthly injections in the other 18 eyes (initial loading dose [+] group). Demographic information and characterization of the patients are shown in Table 1. The CNV was subfoveal in 73.5%
Discussion
In the present study, we demonstrated a significant association between the VEGF rs2010963 genotype and the maintenance of vision after treatment for CNV with anti-VEGF therapy in highly myopic eyes. Parmeggiani et al19 also evaluated the genetic association for response to myopic CNV treatment. They showed a significant association between 2 genes and CNV responsiveness to PDT. Although the results gave us clinically important information, anti-VEGF therapy is now becoming the first choice for
References (39)
- et al.
Etiology of choroidal neovascularization in young patients
Ophthalmology
(1996) - et al.
Myopic choroidal neovascularization: a 10-year follow-up
Ophthalmology
(2003) - et al.
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab
Ophthalmology
(2007) - et al.
Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy
Ophthalmology
(2011) - et al.
Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia
Ophthalmology
(2010) - et al.
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production
Cytokine
(2000) - et al.
Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population
Ophthalmology
(2010) - et al.
Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population
Exp Mol Pathol
(2009) - et al.
Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study
Ophthalmology
(2008) - et al.
Genome-wide association studies reveal genetic variants in CTNND2 for high myopia in Singapore Chinese
Ophthalmology
(2011)
Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment
Am J Ophthalmol
The increasing prevalence of myopia: implications for Australia
Clin Experiment Ophthalmol
Education, socioeconomic status, and ocular dimensions in Chinese adults: the Tanjong Pagar Survey
Br J Ophthalmol
A synopsis of the prevalence rates and environmental risk factors for myopia
Clin Exp Optom
The prevalence of refractive errors among adults in the United States, Western Europe, and Australia
Arch Ophthalmol
Refractive errors in an elderly Japanese population: the Tajimi study
Ophthalmology
A genetic perspective on myopia
Cell Mol Life Sci
Long-term pattern of progression of myopic maculopathy: a natural history study
Ophthalmology
Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia
Br J Ophthalmology
Cited by (0)
Financial Disclosure(s): Supported in part by grants-in-aid for scientific research (Nos. 21249084 and 200791294) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan. The funding organizations had no role in the design or conduct of this research.